• 1
    Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol. 2008; 53: 497-513.
  • 2
    Warde P, Huddart R, Bolton D, Heidenreich A, Gilligan T, Fossa S. Management of localized seminoma, stage I-II: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009 Urology. 2011; 78( 4 suppl): S435-S443.
  • 3
    Wood L, Kollmannsberger C, Jewett M, et al. Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J. 2010; 4: e19-e38.
  • 4
    Martin JM, Panzarella T, Zwahlen DR, Chung P, Warde P. Evidence-based guidelines for following stage 1 seminoma. Cancer. 2007; 109: 2248-2256.
  • 5
    van As NJ, Gilbert DC, Money-Kyrle J, et al. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br J Cancer. 2008; 98: 1894-1902.
  • 6
    Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part I. Eur Urol. 2008; 53: 478-496.
  • 7
    Ackers C, Rustin GJ. Lactate dehydrogenase is not a useful marker for relapse in patients on surveillance for stage I germ cell tumours. Br J Cancer. 2006; 94: 1231-1232.
  • 8
    Trigo JM, Tabernero JM, Paz-Ares L, et al. Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer. 2000; 88: 162-168.
  • 9
    Venkitaraman R, Johnson B, Huddart RA, Parker CC, Horwich A, Dearnaley DP. The utility of lactate dehydrogenase in the follow-up of testicular germ cell tumours. BJU Int. 2007; 100: 30-32.
  • 10
    Gilligan TD, Seidenfeld J, Basch EM, et al. American Society of Clinical Oncology Clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol. 2010; 28: 3388-3404.
  • 11
    Tolan S, Vesprini D, Jewett MA, et al. No role for routine chest radiography in stage I seminoma surveillance. Eur Urol. 2010; 57: 474-479.
  • 12
    Warde P, Gospodarowicz MK, Panzarella T, et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol. 1995; 13: 2255-2262.
  • 13
    Mead GM, Fossa SD, Oliver RT, et al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst. 2011; 103: 241-249.
  • 14
    Aparicio J, Germa JR, Garcia del Muro X, et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol. 2005; 23: 8717-8723.
  • 15
    Bracken RB, Johnson DE, Samuels ML. Alpha fetoprotein determinations in germ cell tumors of testis. Urology. 1975; 6: 382-384.
  • 16
    Javadpour N. Current status of tumor markers in testicular cancer. A practical review. Eur Urol. 1992; 21( suppl 1): 34-36.
  • 17
    Norgaard-Pedersen B, Schultz HP, Arends J, et al. Tumour markers in testicular germ cell tumours. Five-year experience from the DATECA Study 1976-1980. Acta Radiol Oncol. 1984; 23: 287-294.
  • 18
    Schwartz BF, Auman R, Peretsman SJ, et al. Prognostic value of BHCG and local tumor invasion in stage I seminoma of the testis. J Surg Oncol. 1996; 61: 131-133.
  • 19
    Ulbright TM. The most common, clinically significant misdiagnoses in testicular tumor pathology, and how to avoid them. Adv Anat Pathol. 2008; 15: 18-27.
  • 20
    Germa JR, Llanos M, Tabernero JM, Mora J. False elevations of alpha-fetoprotein associated with liver dysfunction in germ cell tumors. Cancer. 1993; 72: 2491-2494.
  • 21
    Morris MJ, Bosl GJ. Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. J Urol. 2000; 163: 796-801.
  • 22
    Trojan A, Joller-Jemelka H, Stahel RA, Jacky E, Hersberger M. False-positive human serum chorionic gonadotropin in a patient with a history of germ cell cancer. Oncology. 2004; 66: 336-338.
  • 23
    Warde P, Gospodarowicz MK, Panzarella T, et al. Long term outcome and cost in the management of stage I testicular seminoma. Can J Urol. 2000; 7: 967-972; discussion 973.
  • 24
    Hartmann M, Pottek T, Bussar-Maatz R, Weissbach L. Elevated human chorionic gonadotropin concentrations in the testicular vein and in peripheral venous blood in seminoma patients. An analysis of various parameters. Eur Urol. 1997; 31: 408-413.
  • 25
    Mumperow E, Hartmann M. Spermatic cord beta-human chorionic gonadotropin levels in seminoma and their clinical implications. J Urol. 1992; 147: 1041-1043.
  • 26
    Weissbach L, Bussar-Maatz R. HCG-positive seminoma. Eur Urol. 1993; 23( suppl 2): 29-32.
  • 27
    Bjurlin MA, August CZ, Weldon-Linne M, Totonchi E. Histologically pure stage I seminoma with an elevated beta-hCG of 4497 IU/L [serial online]. Urology. 2007; 70: 1007, e3-e15.
  • 28
    Bruns F, Raub M, Schaefer U, Micke O. No predictive value of beta-hCG in patients with stage I seminoma—results of a long-term follow-up study after adjuvant radiotherapy. Anticancer Res. 2005; 25( 3A): 1543-1546.
  • 29
    Butcher DN, Gregory WM, Gunter PA, Masters JR, Parkinson MC. The biological and clinical significance of HCG-containing cells in seminoma. Br J Cancer. 1985; 51: 473-478.
  • 30
    Weissbach L, Bussar-Maatz R, Lohrs U, et al. Prognostic factors in seminomas with special respect to HCG: results of a prospective multicenter study. Seminoma Study Group Eur Urol. 1999; 36: 601-608.